Conolidine’s analgesic consequences stem from its interaction with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors in the central nervous system, conolidine modulates alternate molecular targets. A Science Developments review found that conolidine interacts Together with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://henryv157vty5.targetblogs.com/profile